sarcoma

Shorter-Duration Therapy Including Lower-Dose Cyclophosphamide Preserves Efficacy in Newly Diagnosed Low-Risk Rhabdomyosarcoma

Intergroup Rhabdomyosarcoma Study Group (IRSG) studies have shown improved failure-free survival with VAC (vincristine, dactinomycin, and cyclophosphamide) given with a total cumulative cyclophosphamide dose of 26.4 g/m2 compared with VA (vincristine and dactinomycin) in patients with subset 1...

gynecologic cancer
sarcoma

Low Mitotic Count Is an Independent Predictor of Survival in Women With Recurrent Uterine Leiomyosarcoma

Although low mitotic count, surgery, and disease-free interval of more than 6 months were associated with improved survival in women with recurrent or persistent uterine leiomyosarcoma, only low number of mitoses was identified as an independent predictor of survival post relapse, according to...

sarcoma

Reduced Local Recurrence With Intensity-Modulated vs External-Beam Radiation Therapy in Primary Soft-Tissue Sarcomas of the Extremity

There are no large-scale direct comparisons of outcomes with intensity-modulated radiation therapy vs conventional external-beam radiation therapy in patients with soft-tissue sarcoma of the extremity. In a single-institution experience reported in the Journal of Clinical Oncology, Folkert et al at ...

sarcoma

Phase II Study Shows Activity of Hypoxia-Activated Alkylating Prodrug in Combination With Doxorubicin in Advanced Soft-Tissue Sarcoma

In a phase II study reported in the Journal of Clinical Oncology, Chawla et al found that the combination of a hypoxia-activated alkylating prodrug (TH-302) and doxorubicin was active in first-line treatment of advanced soft-tissue sarcoma. TH-302 is a prodrug of the cytotoxic alkylating agent...

sarcoma

Cyclophosphamide Noninferior to Ifosfamide as Part of Consolidation Treatment in Standard-Risk Ewing Sarcoma

In a European phase III noninferiority trial (Euro-EWING99-R1) reported in the Journal of Clinical Oncology, Le Deley et al found that cyclophosphamide was noninferior in event-free survival vs ifosfamide in combination with vincristine/dactinomycin as consolidation therapy in patients with...

multiple myeloma
sarcoma

Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones

A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...

sarcoma
issues in oncology

Tumor-Suppressor Gene TP53 Mutated in 90% of Osteosarcomas

The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project found mutations in the tumor-suppressor gene TP53 in 90% of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The study by Chen et al was...

sarcoma

Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma

Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...

sarcoma

No Overall Survival Benefit of First-Line Doxorubicin Plus Ifosfamide vs Doxorubicin Alone in Advanced Soft-Tissue Sarcoma

In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...

sarcoma

Carbon Ion Radiotherapy Safe and Effective for Treating Inoperable Spinal Tumors

A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. The study, published online in Cancer, indicates that the treatment is a promising alternative for patients whose spinal tumors...

sarcoma

Loss of MicroRNA Decoy Might Contribute to Development of Soft-Tissue Sarcoma

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other...

sarcoma

Nearly Half of Sarcoma Surgeries Performed by Nononcologists

Nearly half the surgical procedures for sarcoma done at 85 academic medical centers were performed by surgeons untrained in oncology, according to national data analyzed by researchers from the University of California Davis Medical Center, Sacramento. Orthopedic oncologists and surgical...

sarcoma

Experimental Drug Beneficial in NIH Trial to Treat a Rare Sarcoma

Patients with advanced alveolar soft part sarcoma achieved some control of their disease using the experimental anticancer drug cediranib. The results from this largest clinical trial on alveolar soft part sarcoma to date were published online ahead of print on April 29, 2013, in the Journal of...

Advertisement

Advertisement

;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.